Insulin Like Growth Factor 1 (IGF-1) Activators Drug Pipeline market Report 2022 Featuring PTC Therapeutics, Ceregene, Hunter-Fleming, Insmed, & Shire - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

"Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2022" offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Insulin Like Growth Factor 1 (IGF-1) Activators development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Insulin Like Growth Factor 1 (IGF-1) Activators

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Insulin Like Growth Factor 1 (IGF-1) Activators

The report assesses the active Insulin Like Growth Factor 1 (IGF-1) Activators pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the Report

• Provides a snapshot of the therapeutics pipeline activity for Insulin Like Growth Factor 1 (IGF-1) Activators
• Features the Insulin Like Growth Factor 1 (IGF-1) Activators pipeline across the complete product development cycle including all clinical and non-clinical stages
• Offers detailed therapeutic product profiles of Insulin Like Growth Factor 1 (IGF-1) Activators with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across Insulin Like Growth Factor 1 (IGF-1) Activators

Key Topics Covered:

1. Report Introduction

2. Insulin Like Growth Factor 1 (IGF-1) Activators - Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for Insulin Like Growth Factor 1 (IGF-1) Activators

4. Comparative Analysis

5. Insulin Like Growth Factor 1 (IGF-1) Activators Pipeline Products in Clinical Stages

• Product Description
• Research and Development
• Product Development Activities

6. Insulin Like Growth Factor 1 (IGF-1) Activators Pipeline Products in Non-clinical Stages

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment: Active Products

• Pipeline Assessment by Route of Administration
• Pipeline Assessment by Stage and Route of Administration
• Pipeline Assessment by Molecule Type
• Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

• Product Description
• Research and Development
• Product Development Activities
• Reason for dormancy/discontinuation

Companies Mentioned

• PTC Therapeutics
• Ceregene
• Hunter-Fleming
• Insmed
• Shire

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/dnzyn8